News | November 03, 2014

SCAI Publishes Consensus Statement on Use of Left Ventriculography

Variation and significant changes in use reflect need for evidence-based expert consensus

November 3, 2014 – Once a common procedure, left ventriculography’s role in assessing heart disease has evolved considerably over the decades, leading to significant variations in use. A new expert consensus statement e-published by the Society for Cardiovascular Angiography and Interventions (SCAI) recommends optimal uses for left ventriculography, with the goal of more standardized use of the test and improved quality of care for cardiac patients.

Left ventriculography is a test in which contrast dye is injected in the heart’s left ventricle through a catheter to aid in capturing images of blood flow out of the left ventricle. The imaging technique was refined in the 1960s and 1970s and became the gold standard for assessing left ventricle function. But newer imaging technology – including cardiac magnetic resonance imaging (MRI), echocardiography and cardiac computed tomographic angiography (CCTA)—has led to reduced use of the test. Use today varies widely both geographically and within hospitals, and there were previously no specific guidelines to aid interventional cardiologists in performing left ventriculography at the time of coronary angiography or left heart catheterization.

“Although use of left ventriculography has declined, there are times when it continues to be a good option for some patients. Previously, no guidelines existed to help physicians understand when and how to use it,” said Osvaldo S. Gigliotti, M.D., FSCAI, the document’s lead author. “The new consensus statement fills the void for guidance on when left ventriculography is the appropriate assessment tool and how it compares to newer imaging tests.”

The paper reviews several uses for left ventriculography, including measurement of ejection fraction, an assessment of how much blood leaves the heart with each pump; identification of defects in the motion of the heart wall; and measurement of ventricle volume in patients with heart valve defects. Left ventriculography is also useful for identifying aneurysms in the left ventricle and septal defects, which are openings between the heart’s chambers.

Authors also discussed alternative imaging techniques, including cardiac MRI, echocardiography, radionuclide ventriculography and CCTA. Echocardiography has become the most commonly used alternate tool for left ventricle assessment, due to its real-time imaging, portability and widespread availability, and because it does not expose the patient to radiation as left ventriculography does.

Echocardiography is also preferred for most pediatric patients. However, left ventriculography remains the best option for children with septal defects, and those with significant vessel abnormalities.

“When compared to other imaging options, left ventriculography should be performed selectively and avoided when adequate alternatives are available,” said Gigliotti. “But there are cases where left ventriculography is essential, such as when a catheter-based device is used to close a septal defect.”

The paper also discusses potential complications and proper technique for left ventriculography. It recommends delivery of contrast dye using power injection, use of a multi-sidehole catheter and sufficient contrast volumes; angulated views to best visualize the heart; positioning the left ventricle in the isocenter of the fluoroscopy system; and having patients hold their breath to minimize motion.

The paper, titled “Optimal Use of Left Ventriculography at the Time of Cardiac Catheterization: A Consensus Statement from the Society for Cardiovascular Angiography and Intervention (SCAI),” is e-published in Catheterization and Cardiovascular Interventions.

For more information: www.scai.org

Related Content

Videos | Cath Lab| January 04, 2018
Bernadette Speiser, BSN, MSN, CCRN, RCIS, a cardiac cath/EP nurse at Palo Alto Veterans Hospital, Palo Alto, Calif.,
FDA Initiates Class I Recall of Sterilmed Reprocessed Agilis Steerable Introducer Sheath
News | Cath Lab| January 04, 2018
The U.S. Food and Drug Administration (FDA) announced a Class I recall of Sterilmed’s Agilis Steerable Introducer...
The California Heart & Vascular Clinic in El Centro, Calif., treated the first post-FDA clearance patient with a DABRA atherectomy system. Athar Ansari, M.D.

The California Heart & Vascular Clinic in El Centro, Calif., treated the first post-FDA clearance patient with a DABRA system. 

Feature | Cath Lab| November 24, 2017 | Athar Ansari, M.D., FACC
As debates about the current state and future of healthcare rage in Congress, the media and healthcare settings acros
Videos | Cath Lab| November 08, 2017
Juan Granada, M.D., Cardiovascular Research Foundation president and chief executive officer, shares his insights on
Results of the ORBITA study found no difference in exercise time after six weeks in patients with stable angina who received percutaneous coronary intervention (PCI) versus a placebo treatment. TCT 2017
Feature | Cath Lab| November 06, 2017
November 6, 2017 – Results from ORBITA, a prospective multi-center randomized blinded placebo-controlled study, found
Culprit Lesion-Only PCI Improves Outcomes for Cardiogenic Shock Patients Compared to Multivessel PCI
News | Cath Lab| November 01, 2017
November 1, 2017 — Results from the prospective, randomized, multicenter CULPRIT-SHOCK trial found an initial strateg
Three-Year Quality of Life Improvements Similar for PCI and CABG in Left Main Disease
News | Cath Lab| October 30, 2017
October 30, 2017 — New study results from the EXCEL trial comparing the quality of life (QoL) of patients with left m
Corindus Evaluates Incorporating HeartFlow Technology With CorPath GRX System
Technology | Cath Lab| October 26, 2017
Corindus Vascular Robotics Inc. announced that it will incorporate the HeartFlow FFRct (fractional flow reserve-...
Shockwave Medical Announces $35 Million in New Financing
News | Cath Lab| October 24, 2017
October 24, 2017 — Shockwave Medical reported $35 million in new financing, an extension of the company’s previously
Overlay Init